[ad_1]
The frenzy that Danish drug maker Novo Nordisk unleashed with its semaglutide medicine Ozempic and Wegovy exhibits little signal of letting up. The weekly injectables—indicated for sort 2 diabetes and weight administration, respectively—are nowhere extra common than in the US. Novo Nordisk’s just-released annual report for 2023 exhibits simply how widespread they’ve grow to be, and the place the corporate goals to go subsequent. Right here, 10 key numbers that inform the story.
36%
Pushed by its semaglutide franchise in North America and different worldwide markets, Novo Nordisk gross sales grew 36% (all numbers are at fixed trade fee) in 2023, to $33.7 billion, versus simply over $25 billion in 2022.
73%
The U.S. market accounts for greater than half of Novo Nordisk’s complete gross sales, and greater than 73% of its gross sales development in 2023.
154%
Gross sales in weight problems medicine—the semaglutide drug Wegovy and an older drug, Saxenda, with a distinct energetic ingredient—have been up 154% in 2023.
7
In 2023, Novo Nordisk launched the injectable weight-loss drug Wegovy in seven new markets exterior the U.S.: Denmark, Norway, Germany, the U.Ok., Switzerland, Iceland, and the United Arab Emirates.
2x
Novo Nordisk says it “greater than doubled” the availability of Wegovy starter doses in 2023. In Could, the corporate needed to restrict starter doses—and paused U.S. TV adverts—as a result of it couldn’t sustain with demand. It’s persevering with to ramp up manufacturing capability, with plans to spend greater than $6.5 billion on supply-chain investments in 2024, up from about $3.8 billion in 2023. The corporate additionally launched a brand new Wegovy industrial, titled “Change Is Never Easy.”
75%
In 2023, 75% of latest prescriptions for Wegovy within the U.S. went to sufferers who have been new to anti-obesity treatment.
50 million
In a convention name with analysts on January 31, Doug Langa, Novo Nordisk’s head of North America operations, mentioned he’s “general happy with the extent of entry” to insurance coverage protection for the corporate’s weight problems medicine. He says 50 million individuals within the U.S. are coated, with about 50% of employers opting in. However well being methods and enormous employers—such because the state of North Carolina, which lately introduced it would cease masking weight-loss medicine for state workers—are more and more involved about excessive prices and surging demand.
33.8%
Novo Nordisk, which celebrated its a hundredth anniversary final 12 months, was constructed on diabetes care. It’s nonetheless the chief in world insulin gross sales, with greater than 45% of the market, and in 2023 it bumped up gross sales throughout its diabetes portfolio to achieve simply over a 3rd, or 33.8%, of the worldwide diabetes market by worth.
18% to 26%
The corporate’s decrease forecast for gross sales development in 2024 accounts for brand spanking new competitors from Eli Lilly’s lately authorised weight-loss drug Zepbound in addition to strain to supply greater rebates to pharmacy profit managers who negotiate costs on behalf of insurers.
$4.7 billion
In 2023, Novo Nordisk boosted R&D spending by 37% over 2022, from about $3.49 billion to roughly $4.7 billion.
18
The corporate stories 18 present Part 3 trials of latest medicine—together with IcoSema and CagriSema, which mix semaglutide with one other drug—and present medicines in new formulations or new indications. These embody trials of each oral and injectable semaglutide for weight problems, liver and kidney illness, and Alzheimer’s illness. Based mostly on its now-completed SELECT trial, Novo Nordisk expects a U.S. choice on the approval of Wegovy to deal with cardiovascular circumstances within the first half of 2024, which might result in broader adoption and elevated insurance coverage protection.
[ad_2]
Source link